EnteroBiotix

EnteroBiotix is a clinical-stage biopharmaceutical company headquartered in Scotland, dedicated to transforming human health through microbiome-based therapeutics. The company focuses on developing orally administered, full-spectrum microbial therapies designed to restore and maintain gut microbial diversity. These therapies are built on the concept of Intestinal Microbial Transfer (IMT), using microbial communities sourced from rigorously screened healthy donors. By leveraging cutting-edge stabilization and manufacturing technologies, EnteroBiotix is able to produce safe, effective, and shelf-stable products that do not require refrigeration or bowel preparation.

Their work is underpinned by a strong technological platform that integrates donor screening, microbial characterization, proprietary drying processes, and GMP-certified manufacturing. This allows for consistent, high-quality production of microbiota-based therapeutics with ambient stability and ease of administration. EnteroBiotix is advancing a clinical pipeline targeting conditions linked to microbiome disruption, including liver cirrhosis and gastrointestinal disorders. Early clinical studies have shown potential in improving gut barrier integrity and reducing markers of systemic inflammation.

With a science-led, patient-focused approach, EnteroBiotix is aiming to redefine how gut microbiota is used in medicine. The company continues to expand its platform and partnerships to accelerate development and bring innovative microbiome therapies to market.

Keywords: EnteroBiotix, microbiome therapeutics, gut health, microbiota restoration, anaerobic bacteria, oral microbial therapy, intestinal microbial transfer, liver cirrhosis treatment, gut-brain axis, microbiome-based drug development, GMP microbiome manufacturing, clinical-stage biotech, Scotland biotech, full-spectrum microbial therapy